Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial.

Souvenaid aims to improve synapse formation and function. An earlier study in patients with Alzheimer's disease (AD) showed that Souvenaid increased memory performance after 12 weeks in drug-naïve patients with mild AD. The Souvenir II study was a 24-week, randomized, controlled, double-blind, parallel-group, multi-country trial to confirm and extend previous findings in drug-naïve patients with mild AD. Patients were randomized 1:1 to receive Souvenaid or an iso-caloric control product once daily for 24 weeks. The primary outcome was the memory function domain Z-score of the Neuropsychological Test Battery (NTB) over 24 weeks. Electroencephalography (EEG) measures served as secondary outcomes as marker for synaptic connectivity. Assessments were done at baseline, 12, and 24 weeks. The NTB memory domain Z-score was significantly increased in the active versus the control group over the 24-week intervention period (p = 0.023; Cohen's d = 0.21; 95% confidence interval [-0.06]-[0.49]). A trend for an effect was observed on the NTB total composite z-score (p = 0.053). EEG measures of functional connectivity in the delta band were significantly different between study groups during 24 weeks in favor of the active group. Compliance was very high (96.6% [control] and 97.1% [active]). No difference between study groups in the occurrence of (serious) adverse events. This study demonstrates that Souvenaid is well tolerated and improves memory performance in drug-naïve patients with mild AD. EEG outcomes suggest that Souvenaid has an effect on brain functional connectivity, supporting the underlying hypothesis of changed synaptic activity.

[1]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[2]  J. Growdon,et al.  Evidence for a membrane defect in Alzheimer disease brain. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[4]  J. Fritschy,et al.  Matching of Pre- and Postsynaptic Specializations during Synaptogenesis , 2007, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[5]  B. Vellas,et al.  Endpoints for trials in Alzheimer's disease: a European task force consensus , 2008, The Lancet Neurology.

[6]  S. Gauthier,et al.  Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. , 1999, The American journal of occupational therapy : official publication of the American Occupational Therapy Association.

[7]  M. Storandt,et al.  A longitudinal EEG study of mild senile dementia of Alzheimer type: changes at 1 year and at 2.5 years. , 1985, Electroencephalography and clinical neurophysiology.

[8]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[9]  P. Scheltens,et al.  Can nutrients prevent or delay onset of Alzheimer's disease? , 2010, Journal of Alzheimer's disease : JAD.

[10]  J. G. van Dijk,et al.  EEG correlates in the spectrum of cognitive decline , 2007, Clinical Neurophysiology.

[11]  R. Wurtman,et al.  Plasma choline concentration varies with different dietary levels of vitamins B6, B12 and folic acid in rats maintained on choline-adequate diets , 2011, British Journal of Nutrition.

[12]  References , 1971 .

[13]  D. Selkoe.  Alzheimer's Disease Is a Synaptic Failure , 2002, Science.

[14]  R. Benedictus,et al.  Uridine enhances neurite outgrowth in nerve growth factor-differentiated PC12 [corrected]. , 2005, Neuroscience.

[15]  C. Stam.  Dementia and EEG , 2012 .

[16]  A. Engel,et al.  Spectral fingerprints of large-scale neuronal interactions , 2012, Nature Reviews Neuroscience.

[17]  G. Sandini,et al.  Graph theoretical analysis of magnetoencephalographic functional connectivity in Alzheimer's disease. , 2009, Brain : a journal of neurology.

[18]  E. Whitham,et al.  Scalp electrical recording during paralysis: Quantitative evidence that EEG frequencies above 20Hz are contaminated by EMG , 2007, Clinical Neurophysiology.

[19]  G. Ramakers,et al.  Neuronal network formation in human cerebral cortex. , 2005, Progress in brain research.

[20]  C J Stam,et al.  Characterization of anatomical and functional connectivity in the brain: a complex networks perspective. , 2010, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[21]  C. Stam,et al.  Phase lag index: Assessment of functional connectivity from multi channel EEG and MEG with diminished bias from common sources , 2007, Human brain mapping.

[22]  R. Wurtman,et al.  Oral supplementation with docosahexaenoic acid and uridine-5′-monophosphate increases dendritic spine density in adult gerbil hippocampus , 2007, Brain Research.

[23]  A. Kiliaan,et al.  Combined uridine and choline administration improves cognitive deficits in spontaneously hypertensive rats , 2003, Neurobiology of Learning and Memory.

[24]  Petra Verhoef,et al.  Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial , 2007, The Lancet.

[25]  P. Scheltens,et al.  Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial , 2010, Alzheimer's & Dementia.

[26]  S H Ferris,et al.  Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. , 1997, Alzheimer disease and associated disorders.

[27]  P. Tariot,et al.  A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease , 2011, Neurology.

[28]  K. Blennow,et al.  Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial , 2008, The Lancet Neurology.

[29]  Martin Koller,et al.  A neuropsychological test battery for use in Alzheimer disease clinical trials. , 2007, Archives of neurology.

[30]  Kenneth J. Pope,et al.  Thinking activates EMG in scalp electrical recordings , 2008, Clinical Neurophysiology.

[31]  S. DeKosky,et al.  Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity , 1990, Annals of neurology.

[32]  R. Benedictus,et al.  Uridine enhances neurite outgrowth in nerve growth factor-differentiated pheochromocytoma cells , 2005, Neuroscience.

[33]  C. Stam,et al.  Small-world networks and functional connectivity in Alzheimer's disease. , 2006, Cerebral cortex.

[34]  J. Pettegrew,et al.  Brain Membrane Phospholipid Alterations in Alzheimer's Disease , 2001, Neurochemical Research.

[35]  P. Scheltens,et al.  Utility of imaging for nutritional intervention studies in Alzheimer's disease. , 2011, European journal of pharmacology.

[36]  Nick C Fox,et al.  Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.

[37]  C.P.G.M. de Groot,et al.  Effect of fish oil supplementation on cognitive performance in older subjects: a randomized, double-blind, placebo-controlled trial , 2008 .

[38]  C. Adler,et al.  Quantitative EEG as a predictive biomarker for Parkinson disease dementia , 2011, Neurology.

[39]  R. Wurtman,et al.  Use of phosphatide precursors to promote synaptogenesis. , 2009, Annual review of nutrition.

[40]  Katherine E. Prater,et al.  Functional connectivity tracks clinical deterioration in Alzheimer's disease , 2012, Neurobiology of Aging.

[41]  P. Scheltens,et al.  Efficacy of a medical food on cognition in Alzheimer’s Disease: Results from secondary analyses of a randomized, controlled trial , 2011, The journal of nutrition, health & aging.

[42]  F. Schmitt,et al.  Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment , 2006, Neurobiology of Aging.

[43]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.